| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 804703 | 25 ug | $245 | ||
| 804704 | 100 ug | $595 |
| Application | FC |
|---|---|
| Format | Liquid, APC |
| Expression Host | CHO |
| Target Name | TNFRSF8, CD30, Ki-1 |
| Species | Human |
| Sources | Recombinant Human CD30 protein (phe19-Lys379) with C-terminus His tag is expressed in CHO cells and conjugated to APC. |
| Accession Number | P28908 |
| Molecular Weight | The protein has a predicted molecular weight of 40 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag | C-His |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months. |
CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-kB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.
APC Conjugated Human CD30/TNFRSF8 Protein (C-His) TDS
Have a product or application question? Consult our FAQs or contact us.
